肠促胰素与骨质疏松

Incretin and osteoporosis

正常人体骨量的维持依赖于成骨细胞新骨生成与破骨细胞骨吸收的骨重建过程。凡是能增加骨吸收、减少骨生成的因素均能使骨密度降低，进而发生骨质疏松。肠促胰素主要由胰高血糖素样肽（GLP）和葡萄糖依赖性促胰岛素多肽（GIP）组成。最新研究发现，GIP及GLP-1均能抑制骨吸收过程，同时促进骨的生成，而目前的研究显示，GLP-2仅对骨吸收有抑制作用。

Normal human bone mass is maintained by the process of bone remodeling, including bone formation and bone resorption. Factors which increase bone resorption and reduce bone formation could reduce bone mineral density, and thus resulting in osteoporosis. Incretin is secreted by the intestinal cells, which can stimulate insulin secretion and regulate glycometabolism. Incretin includes glucagon-like peptide （GLP） , and glucose-dependent insulinotropie polypeptide（GIP）. GIP and GLP-1 can inhibit bone resorption, while promoting bone formation, and the current study shows that GLP-2 only inhibits bone resorption.